CG0070
Phase 3Biologic
CG0070 is one of 89 biologic programs targeting Bladder Cancer. It is currently in Phase 3.
3
Indications
5
Total Trials
2
Active Trials
88
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
378 competitors in Bladder Cancer
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Taxol
TevaPhase 3
Trexall
Alnylam PharmaceuticalsPhase 3
Adriamycin
PfizerPhase 3
Javlor
Bristol-Myers SquibbPhase 3
Taxotere
AAvyxa
Phase 3
Paraplatin
AAvyxa
Phase 3
Mitomycin C
GGynecologic Oncology Group
Phase 3
Cetrelimab
Johnson & JohnsonPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Bladder Cancer2 trials
Safety and Efficacy1 trial
Non Muscle Invasive Bladder Cancer1 trial
A Phase 1b, Single Arm Study of CG0070 After Transurethral Resection in Patients With Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT06253845·20 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CG0070. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- CCG Oncology, Inc.